Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VRC01 and VRC01LS in Healthy Adults
NCT02797171Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2017
- Primary completion
- Jun 2019
- Modality
- Anti-infectious Disease mAbs
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of VRC01LS in human immunodeficiency virus infection (HIV) (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms and 5 more. Started Mar 2017; status: completed.
02
Drugs
VRC01LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02797171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797171.